Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 1, 2001, Pages 30-37

  Sadler, B M ^a   Gillotin, C ^a   Lou, Y ^a   Stein, D S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; LAMIVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CARBAMATES; DIDEOXYNUCLEOSIDES; FEMALE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; MALE; RNA, VIRAL; SULFONAMIDES;

EID: 0035174709     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.1.30-37.2001     Document Type: Article

References (19)

1. Amprenavir
2. A Bayesian analysis of the minimum AIC procedure
3. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
4. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
5. HIV-protease inhibitors
6. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV positive patients
7. Assessment of dose proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Part
8. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
9. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults
10. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy
11. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
12. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
13. 1-Acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV)
14. Plasma protein binding displacement interactions - Why are they still regarded as clinically important?
15. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
16. Pharmacokinetics of 141W94 after multiple dosing in patients with HIV infection: A preliminary report
17. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
18. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging double-blind, randomized, monotherapy trial in human immunodeficiency virus-infected subjects
19. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design